TY - JOUR

T1 - First experience with the Hugo™ robot-assisted surgery system for endometriosis

T2 - A descriptive study

AU - Olsen, Rikke Groth

AU - Hartwell, Dorthe

AU - Dalsgaard, Torur

AU - Madsen, Mette Elkjær

AU - Bjerrum, Flemming

AU - Konge, Lars

AU - Røder, Andreas

N1 - Publisher Copyright: © 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).

PY - 2024

Y1 - 2024

N2 - Introduction: The Medtronic Hugo™ Robot-assisted Surgery (RAS) system was recently approved for clinical use. We explored the safety and feasibility of this system for endometriosis surgery. The primary outcome was safe case completion without major surgical complications (Clavien–Dindo grade ≤2) and no conversion to open surgery or laparoscopy. Material and methods: Surgeries for endometriosis performed at the Department of Gynecology, Rigshospitalet, on the Medtronic Hugo™ RAS system were included. Two experienced robotic surgeons performed all surgeries with their usual robotic team. The variables included were patient demographics, peri- and postoperative data, complications and 30-day readmission rate. We used the IDEAL framework 1/2a for surgical innovation in this descriptive study. Results: The first 12 patients were included. All cases were completed without intraoperative complications or conversion. Four patients experienced Clavien–Dindo grade 1 postoperative complications. No patients were re-admitted within 30 days. Median docking time (17 minutes), console time (87.5 minutes), blood loss (40 mL) and length of hospital stay (1 day) were acceptable compared with previous literature. Conclusions: In this pilot study, we found the Medtronic Hugo™ RAS system safe and feasible for robot-assisted surgery for endometriosis. The advent of new robotic systems is welcomed to accelerate the development of technology that will advance surgical care for patients across the globe.

AB - Introduction: The Medtronic Hugo™ Robot-assisted Surgery (RAS) system was recently approved for clinical use. We explored the safety and feasibility of this system for endometriosis surgery. The primary outcome was safe case completion without major surgical complications (Clavien–Dindo grade ≤2) and no conversion to open surgery or laparoscopy. Material and methods: Surgeries for endometriosis performed at the Department of Gynecology, Rigshospitalet, on the Medtronic Hugo™ RAS system were included. Two experienced robotic surgeons performed all surgeries with their usual robotic team. The variables included were patient demographics, peri- and postoperative data, complications and 30-day readmission rate. We used the IDEAL framework 1/2a for surgical innovation in this descriptive study. Results: The first 12 patients were included. All cases were completed without intraoperative complications or conversion. Four patients experienced Clavien–Dindo grade 1 postoperative complications. No patients were re-admitted within 30 days. Median docking time (17 minutes), console time (87.5 minutes), blood loss (40 mL) and length of hospital stay (1 day) were acceptable compared with previous literature. Conclusions: In this pilot study, we found the Medtronic Hugo™ RAS system safe and feasible for robot-assisted surgery for endometriosis. The advent of new robotic systems is welcomed to accelerate the development of technology that will advance surgical care for patients across the globe.

KW - endometriosis

KW - gynecological surgery

KW - Hugo™ RAS

KW - IDEAL framework

KW - robotic surgical procedures

U2 - 10.1111/aogs.14727

DO - 10.1111/aogs.14727

M3 - Journal article

C2 - 38031442

AN - SCOPUS:85178218077

VL - 103

SP - 368

EP - 377

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 2

ER -